Replies to post #1815 on Benitec Biopharma Ltd (BNTC)

[Blane]

Because at the moment, it is an Australian listed company, and as such, is succeptible to manipulation. Until the IPO happens, or other major news, the price will probably drop, as manipulators continue to accumulate cheap shares. This is why the U.S. IPO is significant. It will provide this stock with more stability and less manipulation. Also, when efficacy data comes in, we will be even more appropraiately valued.

[Bobwins]

Australian investors don't like the dilution that looks likely to happen with the US IPO. Therefore those that are wary of the dilution are selling. Whether the stock will be less likely to have manipulation after the IPO is uncertain.

Holders are anticipating positive news from the company's Hep C trial in December but there's no guarantee that the results will delight the markets. Definitely US investors value biotech more than Australian investors so the US exposure should help the stock as long as results from the trial are positive and the trial moves forward at the anticipated pace.